Generation of multiple angiogenesis inhibitors by human pancreatic cancer

Cancer Research

Volumn 61, Issue 19, 2001, Pages 7298-7304

  Kisker, Oliver ^a,b   Onizuka, Shinya ^a,c   Banyard, Jacqueline ^a   Komiyama, Tomoko ^b   Becker, Christian M ^a,d   Achilles, Eike Gert ^a,e   Barnes, Carmen M ^a   O’Reilly, Michael S ^f   Folkman, Judah ^a,g   Pirie Shepherd, Steven R ^a,h  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c NAGASAKI UNIVERSITY   (Japan)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF TEXAS   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h Attenuon LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; PLASMINOGEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CHORIOALLANTOIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTITHROMBINS; CARCINOMA, LEWIS LUNG; CELL DIVISION; CHICK EMBRYO; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; FIBROSARCOMA; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035476261     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. What is the evidence that tumors are angiogenesis dependent?
2. Angiogenesis in cancer, vascular, rheumatoid and other disease
3. Induction of angiogenesis during the transition from hyperplasia to neoplasia
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Angiogenesis and tumor metastasis
6. Breast cancer metastasis-associated genes: Role in tumor progression to the metastatic state
7. Lymphatic dissemination of hepatic metastases. Implications for the follow-up and treatment of patients with colorectal cancer
8. Inhibition of metastases by a serum factor associated to concomitant resistance induced by unrelated murine tumors
9. The suppression of tumor metastases by a primary tumor
10. A strategy to discover circulating angiogenesis inhibitors generated by human tumors
11. Antiangiogenesis and apoptosis as mediators of concomitant tumor resistance induced by Calu-6, a human lung carcinoma cell line, in nude mice
12. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
13. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
14. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin
15. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
16. Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma
17. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes
18. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa
19. Analysis of protein conformation by gel electrophoresis
20. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane
21. Angiostatin generation by human pancreatic cancer
22. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins
23. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
24. Human plasma proteinase inhibitors
25. Mobile reactive centre of serpins and the control of thrombosis
26. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A
27. The use of α 2-antiplasmin as a model for the demonstration of complex reversibility in serpins
28. The effect of α 2-macroglobulin on the interaction of α I-proteinase inhibitor with porcine trypsin
29. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells
30. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
31. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
32. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
33. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
34. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
35. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells
36. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase
37. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
38. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer
39. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells
40. The hemostatic system as a regulator of angiogenesis
41. Thrombosis and cancer
42. Hemostatic abnormalities associated with cancer and its therapy
43. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines
44. Limited proteolysis of α 1-proteinase inhibitor (α 1-PI) in acute leukemia: Studies on the resulting fragments and implication for the structure of the inactivated inhibitor